Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth
Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth
About this item
Full title
Author / Creator
Publisher
United States: American Diabetes Association
Journal title
Language
English
Formats
Publication information
Publisher
United States: American Diabetes Association
Subjects
More information
Scope and Contents
Contents
Recently, pleiotropic benefits of incretin therapy beyond glycemic control have been reported. Although cancer is one of the main causes of death in diabetic patients, few reports describe the anticancer effects of incretin. Here, we examined the effect of the incretin drug exendin (Ex)-4, a GLP-1 receptor (GLP-1R) agonist, on prostate cancer. In h...
Alternative Titles
Full title
Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1616482264
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1616482264
Other Identifiers
ISSN
0012-1797
E-ISSN
1939-327X
DOI
10.2337/db13-1169
